Opko Health’s subsidiary BioReference Laboratories has launched a new multiplex test that will aid healthcare providers, clinics and health systems in the diagnosis …
BioReference Laboratories, a wholly-owned subsidiary of Opko Health, has commenced its COVID-19 testing program for New York City public schools. The testing will …
Since 2019, the healthcare sector has been bracing for the wild ride that would be the election year. However, according to some Street …
Opko Health announced the initiation of a Phase 2 trial of Rayaldee as a treatment for mild-to-moderate COVID-19. After rising in the pre-market …
Dark clouds are looming over Wall Street, and the storm only appears to be intensifying. The market was dealt another blow on Wednesday …
It has been an ugly day for the markets in the past few days. The biotech sector has been particularly hard hit.
Is Billionaire fund guru Jim Simons switching OPK for VRX?
Louise Chen: Even with less-than-impressive sales for the quarter, OPK stock still poses long-term value.
Opko Health Inc. (NASDAQ:OPK) reports operating and financial results for the three months ended September 30, 2017.
Louise Chen notes that under OPK’s agreement with Tesaro, the approval of Varubi IV is a huge win.